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Heart and lung exposurea b s t r a c t
Background and purpose: Adjuvant radiotherapy of internal mammary nodes (IMN) improves survival in
high-risk early breast cancer patients but inevitably leads to more dose to heart and lung. Target coverage
is often compromised to meet heart/lung dose constraints. We estimate heart and lung dose when target
coverage is not compromised in consecutive patients. These estimates are used to guide the choice of
selection criteria for the randomised Danish Breast Cancer Group (DBCG) Proton Trial.
Materials and methods: 179 breast cancer patients already treated with loco-regional IMN radiotherapy
from 18 European departments were included. If the clinically delivered treatment plan did not comply
with defined target coverage requirements, the plan was modified retrospectively until sufficient cover-
age was reached. The choice of selection criteria was based on the estimated number of eligible patients
for different heart and lung dose thresholds in combination with proton therapy capacity limitations and
dose–response relationships for heart and lung.
Results: Median mean heart dose was 3.0 Gy (range, 1.1–8.2 Gy) for left-sided and 1.4 Gy (0.4–11.5 Gy)
for right-sided treatment plans. Median V17Gy/V20Gy (hypofractionated/normofractionated plans) for
ipsilateral lung was 31% (9–57%). The DBCG Radiotherapy Committee chose mean heart dose  4 Gy
and/or lung V17Gy/V20Gy  37% as thresholds for inclusion in the randomised trial. Using these
Line Bjerregaard Stick, Ebbe Laugaard Lorenzen, Esben Svitzer Yates et al. Clinical and Translational Radiation Oncology 27 (2021) 126–131thresholds, we estimate that 22% of patients requiring loco-regional IMN radiotherapy will be eligible for
the trial.
Conclusion: The patient selection criteria for the DBCG Proton Trial are mean heart dose  4 Gy and/or
lung V17Gy/V20Gy  37%.
 2021 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Irradiation of lymph nodes including the internal mammary
nodes (IMN) improves overall and disease-free survival rates in
high-risk breast cancer patients in a meta-analysis of the ran-
domised EORTC 22922/10925 and NCIC-CTG MA.20 trials [1–4].
This is consistent with results from the population-based Danish
Breast Cancer Group (DBCG) IMN trial demonstrating that IMN
irradiation improves overall survival and reduces breast cancer
mortality [5]. However, IMN irradiation can cause larger radiation
exposure to the heart which in turn increases the risk of radiation-
induced toxicity [6–10]. Likewise, lymph node irradiation increases
the dose to the lung which can lead to second lung cancer [11,12].
Modern radiotherapy techniques can improve the balance between
target coverage and exposure to heart and lung [13–15]. Still, it is
sometimes necessary to compromise the IMN coverage to comply
with dose constraints for heart and lung defined in treatment plan-
ning guidelines.
Proton therapy has not been widely used for adjuvant breast
cancer radiotherapy, thus the evidence supporting its clinical
use is limited [16–23]. The properties of spot-scanning proton
therapy allow adequate target coverage and low dose to the heart
and lung compared with photon radiotherapy, independently of
patient anatomy as demonstrated in a comparative planning
study with 41 consecutive high-risk breast cancer patients [24].
Hence, there is no need for immediate individual proton therapy
comparison if a photon radiotherapy plan has a high heart or lung
dose. Recent treatment planning studies show limited benefit of
spot-scanning proton therapy in deep inspiration breath-hold
(DIBH) versus free breathing for patients with breast cancer
[25,26].
The majority of breast cancer patients receive exemplary treat-
ment with state-of-the-art photon radiotherapy techniques [13–
15], but a subgroup of patients may have an additional clinically
relevant benefit from proton therapy [24–29]. The strategy in the
DBCG Proton Trial is to randomise highly selected patients
between photon radiotherapy and proton therapy (ClinicalTrials.-
gov number, NCT04291378) [30]. The DBCG Radiotherapy Com-
mittee decided that patients with treatment plans showing high
dose to heart and/or lung to fulfil adequate target coverage
should be offered participating in the trial. No treatment plan
comparison will be needed before randomisation in the trial
assuming that proton therapy provides low exposure of heart
and lung [24]. Compromises in target coverage to reduce dose
to heart or lung are allowed after randomisation in the photon
therapy plan, because that reflects clinical practice according to
the DBCG guidelines.
In this study, we estimate heart and lung dose when target cov-
erage is not compromised in consecutive breast cancer patients
receiving loco-regional irradiation to guide the choice of dose
selection criteria for the DBCG Proton Trial. The choice of dose
selection criteria was based on these heart and lung dose estimates
in combination with capacity limitations for proton therapy and
considerations of dose–response relationships for heart and lung.
The trial is open for international participation, and the trial proto-
col is available here [30].1272. Materials and methods
2.1. Patients
Patient data were collected retrospectively from 18 radiother-
apy departments in six European countries including all seven
Danish departments (see list of departments in Supplementary
Materials). Breast cancer patients who were treated with whole
breast or chest wall loco-regional radiotherapy including IMNwere
included in the study. Tumour bed boosts were allowed. Each
department identified in May/June 2018 the five most recently
treated patients with left-sided breast cancer and the five most
recently treated patients with right-sided breast cancer for the ret-
rospective analysis. If patients were re-planned during the course,
the plan used for most fractions was chosen. Target contour delin-
eations were performed following the ESTRO consensus guidelines
[31]. Planning target volumes (PTV) in 3DCRT were not used in all
centres; a distance of 10 mm between CTV and multileaf collimator
(MLC) was applied instead.
2.2. Treatment plan modification
If fully or partly field-based planning was used (i.e. planned
without target contours), missing target contours were delineated
retrospectively for the purpose of this study. Target contours were
re-delineated if they had been delineated without following the
ESTRO consensus guidelines.
Treatment plans were modified if they did not comply with the
DBCG constraints below for the clinical target volumes (CTV):
a) 95% of the IMN CTV covered by 90% dose
b) 95% of the lymph node CTV covered by 90% dose
c) 95% of the whole breast CTV or chest wall CTV covered by
95% dose
Treatment plan modifications were made at the treating depart-
ment. Modifications for 3D conformal radiotherapy (3DCRT) tech-
nique was performed by re-fitting the MLC to cover the whole
target if parts of the target had been shielded by the MLC to reduce
dose to heart or lung (see Fig. 1). Extra segments were added if the
modified treatment plan still did not comply with the defined tar-
get constraints. Treatment plan modifications for inverse planning
techniques were made by re-optimising the plan such that it met
the defined target constraints.
2.3. Data reporting
Dose-volume data were reported as DICOM files through the
Danish treatment plan bank (seven departments), by text files with
dose-volume histogram data (five departments) or by dose report-
ing scheme (six departments) during May and June 2018. See dose
reporting schemes in Table A1-A3 in Supplementary Materials. The
following additional information about the treatment was
reported: laterality, surgery, irradiated lymph node levels, number
of intercostal spaces in the IMN CTV, dose-fractionation scheme,
boost, treatment planning technique, use of breath-hold or gating,
Fig. 1. Example of 3DCRT plan modification from beams eye view. Clinical treatment plan (left panel): The heart (yellow structure) is shielded by the multileaf collimators,
and the IMN (cyan structure) are partially shielded. Modified treatment plan (right panel): the IMN are fully covered. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
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defined target constraints. Dose-volume data from treatment plans
prior to modification were not included. Mean doses to heart and
lung were re-normalised to prescription dose of 40 Gy such that
mean doses from 50 Gy plans were reduced to 80% in Fig. A1 in
Supplementary Material.2.4. Choice of patient selection criteria
The DBCG Radiotherapy Committee chose to focus on heart
and lung dose estimates from departments having 3DCRT and
DIBH or enhanced inspiration gating (EIG) [15] as standard since
these techniques by far are the most predominant in all Danish
departments. To simplify the use of the selection criteria in daily
clinical routine, the Committee decided that the dose thresholds
should be the same for normofractionated and moderate
hypofractionated dose-fractionation schemes and that the thresh-
olds should be integer numbers. To guide the choice of patient
selection criteria, the DBCG Radiotherapy Committee balanced
the estimated number of eligible patients for different dose
thresholds with limitations in capacity for proton therapy at the
Danish Centre for Particle Therapy and the current knowledge
of dose–response relationships for heart [6–10] and lung
[11,12]. The assumptions regarding the number of eligible
patients needed were as follows: We assumed that the majority
of patients with excessive heart and lung exposure would be
patients requiring loco-regional irradiation and additional
patients with synchronous bilateral breast cancer or with com-
plex anatomy, such as pectus excavatum [32]. The capacity limi-
tation at Danish Centre for Particle Therapy was approximately
100 patients per year corresponding to 200 patients included in
the trial each year when randomising patients 1:1. We assumed
that roughly 75% of the eligible patients would willing to partic-
ipate in the trial. More than 3500 breast cancer patients receive
adjuvant radiotherapy in Denmark each year, and approximately
35% of the patients have indication for loco-regional irradiation.
Following these assumptions, we should identify roughly 22% of
the patients requiring loco-regional irradiation (corresponding
to approximately 8% of all breast cancer patients referred to
radiotherapy) as candidates for proton therapy.1283. Results
A total of 180 breast cancer patients treated with adjuvant loco-
regional radiotherapy including the IMN were included in the
study. One patient was excluded due to technical problems with
data reporting. The prescription dose ranged from 39.9 Gy to
51.52 Gy in 15 to 28 fractions. Planning techniques included 3DCRT
and several inversely optimised techniques: volumetric modulated
arc therapy (VMAT), hybrid planning technique (combination of
3DCRT and VMAT), intensity modulated tomotherapy and step &
shoot intensity modulated radiotherapy (IMRT) + static supraclav-
icular field. Sixty-three percent of the patients were treated in
DIBH or EIG. Nine of the participating departments aimed at treat-
ing patients with 3DCRT using DIBH/EIG; 98% of the patients from
these nine departments were treated with 3DCRT and 93% of them
were treated using DIBH/EIG. Forty out of 90 plans were nor-
mofractionated and 50 were hypofractionated. The remaining nine
departments treated mainly patients with inverse optimised tech-
niques; 98% of these patients were treated with inverse optimised
techniques, and 31% of the patients were treated using DIBH/EIG).
Target contours were (re-)delineated in 30 treatment plans
from three departments, and these plans were all modified to fulfil
the DBCG target coverage constraints. Additional 41 treatment
plans needed modification to comply with the target coverage con-
straints. Treatment characteristics are provided in Table 1.
It was not possible to achieve the required coverage of the
whole breast or chest wall CTV (95% of the whole breast or chest
wall CTV should be covered by 95% dose) for five patients in whom
V95% (the volume percentage that received 95% of the prescription
dose) ranged from 87% to 94% due to underdosage in superficial
parts of the target.
In the revised treatment plans, median mean heart dose was
3.0 Gy (range, 1.1 to 8.2 Gy) for left-sided breast cancer and
1.4 Gy (0.4 to 11.5 Gy) for right-sided breast cancer (see Fig. 2).
Median mean heart dose was 2.8 Gy (1.1 to 7.4 Gy) for left-sided
breast cancer using DIBH or EIG (35% of all patients) and 5.2 Gy
(2.2 to 8.2 Gy) for left-sided breast cancer not using DIBH or EIG
(15% of all patients). Median mean dose to ipsilateral lung was
13.4 Gy (5.1 to 24.9 Gy). Median V17Gy/V20Gy (V17Gy for
hypofractionated plans and V20Gy for normofractionated plans)
for ipsilateral lung was 31% (9 to 57%). Fig. A1 in Supplementary
Table 1
Treatment characteristics. *50 Gy in 25 fractions included patients receiving
51.52 Gy in 28 fractions (n = 3), 40 Gy in 15 fractions included patients
receiving 42.3 Gy in 18 fractions (n = 2) and other dose-fractionation
schemes included 42.56 Gy in 16 fractions (n = 3), 45.57 Gy in 21 fractions
(n = 4), 44.6 Gy in 22 fractions (n = 1) and 50.4 Gy in 28 fractions (n = 1). yAll
boosts were simultaneous integrated boosts. DIBH (n = 102) and EIG
(n = 10). §Partly field-based planning used i.e. lymph node target was not
delineated (n = 20), and initial target delineations did not follow the ESTRO
consensus guidelines (n = 10). p
p
30 out of 71 treatment plans had modified
target delineations. Abbreviations: n, number of patients; 3DCRT, 3D
conformal radiotherapy; VMAT, volumetric modulated arc therapy; IMRT,
intensity modulated radiotherapy; SCF, supraclavicular field; DIBH, deep




Left-sided breast cancer 89 (50%)
Right-sided breast cancer 90 (50%)
Dose-fractionation scheme*
50 Gy in 25 fractions 69 (39%)
40 Gy in 15 fractions 101 (56%)








Intensity modulated tomotherapy 35 (20%)







Mastectomy + reconstruction 19 (11%)
Treated lymph node levels
IMN 179 (100%)
Axilla level 1 60 (34%)
Axilla level 2 131 (73%)
Axilla level 3 177 (99%)
Lymph node level 4 177 (99%)
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normalised to a prescription dose of 40 Gy in 15 fractions.
The percentage of plans exceeding several heart and lung dose
thresholds in departments having 3DCRT and DIBH/EIG as stan-
dard can be seen Table 2. The DBCG Radiotherapy Committee
decided that the patient selection criteria for the DBCG Proton Trial
were mean heart dose  4 Gy and/or ipsilateral lung V17Gy/V20
Gy  37% corresponding to 22% of the patients (20 out of 90
patients) being eligible for the trial. Twelve of these 20 patients
had left-sided breast cancer, 11 had a mean heart dose  4 Gy (9
out of 11 had left-sided breast cancer) and 12 had lung V17Gy/V
20Gy  37%. For the nine departments using inversely optimised
treatment techniques as standard, 54% of the patients had mean
heart dose  4 Gy and/or lung V17Gy/V20Gy  37%. In total, 68
of out of 179 patients exceeded the dose thresholds for heart and
lung defined in patient selection criteria for the DBCG Proton Trial.1294. Discussion
This retrospective study estimates heart and lung doses when
target coverage is not compromised in 179 high-risk breast cancer
patients receiving loco-regional IMN radiotherapy. Sixty percent of
the treatment plans did already comply with the delineation
requirements and the DBCG target coverage constraints, and, thus,
60% of the reported heart and lung doses were from clinically
delivered treatment plans. The need for treatment plan modifica-
tion was seen among most participating departments implying
that compromises on target coverage to lower the dose to the
organs at risk were routinely performed in daily clinic despite of
reduced probability of disease control [2–5,33]. For the purpose
of this study, these treatment plans were modified to meet target
coverage constraints according to DBCG guidelines and the quality
of these plans is therefore variable. Still, we believe that this
method was the best way to provide the dose estimates needed
to guide the choice of selection criteria for the DBCG Proton Trial.
Various treatment planning techniques were used for the
patients in the participating departments. As a result, after recog-
nising the heterogeneity among the treatment plans, we decided
to guide our selection criteria based on departments aiming for
treatment with 3DCRT in DIBH/EIG. In this work we have pre-
sented the full range of data analyzed in the process of setting
up the inclusion criteria. This is done to illustrate the wide range
of OAR doses seen in actual clinical use in the participating centers,
which both informed our process and may be of interest to the
community in general. For setting up the actual inclusion criteria
we chose to focus on 3DCRT plans, as this is by far the dominant
technique used in the Danish sites, which will include patients in
the study. The reason for not simply use all patients treated with
3DCRT in DIBH was that difficult patient anatomies were usually
handled with VMAT or hybrid planning technique in these depart-
ments and not all patients can comply with DIBH. Tumour bed
boosts might come with increased exposure of heart and lung.
However, we chose not to exclude patients receiving tumour bed
boosts in this study since these patients reflected the variation in
heart and lung irradiation seen across patients in the clinic. It
was not possible to obtain the required target coverage for five
patients, but we decided not to exclude these patients to resemble
the heterogeneity among patient anatomies in daily clinical
routine.
To ease the use of the patient selection criteria in daily clinical
practice, the DBCG Radiotherapy Committee decided to choose
integer numbers as dose thresholds that were independent of
40 Gy in 15 fractions or 50 Gy in 25 fractions [34]. This implies that
the 4 Gy mean heart dose threshold is 10% of prescription dose for
40 Gy treatments and 8% of prescription dose for 50 Gy treatments.
Thus, it can be argued that it is more unbiased to use a relative
heart dose threshold or even an equivalent dose in 2 Gy fractions
(EQD2) threshold. On the other hand, from an EQD2 point of view,
the 4 Gy mean heart dose threshold is, within reasonable uncer-
tainties, about equivalent between the two dose-fractionation
schemes, even though it is not the actual EQD2 dose but rather
the physical dose. A V17Gy threshold for 40 Gy treatments and a
V20Gy for 50 Gy treatment were used following DBCG lung con-
straints. Breast only radiotherapy data from DBCG HYPO Trial have
recently shown similar values when using V17Gy in 40 Gy plans
and V20Gy in 50 Gy plans [35] suggesting that a shared dose met-
ric can be used for both fractionation schemes. The DIBH technique
has the potential to reduce dose to heart and lung [13,14] and
should be examined before considering proton therapy for the
patient.
Modern loco-regional radiotherapy for breast cancer is associ-
ated with high survival rates and most patients become long-
Fig. 2. Each panel shows mean heart dose versus V17Gy/V20Gy for ipsilateral lung for the 179 revised treatment plans fulfilling the DBCG target coverage constraints. The
patients are divided in categories: A) left- versus right-sided breast cancer, B) 3DCRT versus inverse treatment techniques and DIBH and EIG versus no DIBH or EIG (right
panel). The dashed lines represent the median mean heart dose for each category, and the dotted lines represent the median ipsilateral lung V17Gy/V20Gy for each category.
The grey areas show patients with doses lower than the mean heart dose = 4 Gy and lung V17Gy/V20Gy = 37% thresholds.
Table 2
Percentage of patients exceeding heart and/or lung dose thresholds in departments having 3DCRT and DIBH/EIG as standard. Note that only one of the two thresholds needs to be
exceed. Based on the defined dose thresholds for the DBCG Proton Trial (mean heart dose  4 Gy and/or lung V17Gy/V20Gy  37%), 22% of the breast cancer patients treated with
loco-regional RT including the IMN are eligible for participation in the trial.
MHD Ipsilateral lung V20Gy/V17Gy >1 Gy >2 Gy >3 Gy >4 Gy >5 Gy >6 Gy
>25% 94% 92% 92% 91% 91% 91%
>30% 84% 72% 67% 63% 63% 63%
>35% 73% 49% 34% 28% 24% 20%
>36% 72% 48% 32% 26% 22% 18%
>37% 72% 46% 29% 22% 19% 14%
>38% 72% 41% 24% 18% 14% 10%
>39% 72% 41% 24% 18% 14% 10%
>40% 72% 40% 22% 16% 12% 8%
>45% 71% 38% 19% 12% 9% 4%
Line Bjerregaard Stick, Ebbe Laugaard Lorenzen, Esben Svitzer Yates et al. Clinical and Translational Radiation Oncology 27 (2021) 126–131term cancer survivors [2,4,5]. This means that even small excess
absolute risks for late radiation-induced toxicity should be consid-
ered. The study by Darby et al. estimates that a mean heart dose of
4 Gy in a 50-year-old breast cancer patient with cardiac risk factor
would increase her risk of experiencing an acute coronary event
before the age of 80 years from 8.0% to 10.2% and increase her risk
of death from ischemic heart disease before the age of 80 years
from 3.4% to 4.3% [6]. Likewise, the study by Taylor et al. estimates
that a mean lung dose of 5 Gy to the whole lung in a 50-year-old
ever-smoker breast cancer patient would increase her risk of death
from lung cancer before age of 80 years from 9.4% to 13.8% [12].
The DBCG Radiotherapy Committee did consider using pre-
dicted benefit in normal tissue complication probability (NTCP)
for patient selection in the DBCG Proton Trial following the Dutch
model-based proton selection strategy [36,37] of radiation-
induced ischemic heart disease as criteria. In the Netherlands
breast cancer patients can be referred to proton therapy if they
have a predicted DNTCP  2% of acute coronary event at age 80
as defined in the study by Darby et al. [6]. Model-based selection
allows the inclusion of patient-specific factors, such as age and car-
diac risk factors. However, it was decided to use only dosimetric
parameters due to large uncertainties in the risk modelling (espe-
cially, if including cardiac risk factors). Hopefully, the extensive
data collection of baseline information about lifestyle and comor-
bidities in the DBCG Proton Trial will provide data for establishing
NCTP models in the future. The UK Breast Proton Beam Therapy
Group will use internationally harmonised dose thresholds (mean
heart dose of  4 Gy and/or ipsilateral lung V17Gy  35%) in the
trial PARABLE (Proton beAm theRApy in patients with Breast can-
cer: Evaluating early and Late-Effects). The committee acknowl-
edges that there is currently no optimal objective answer to the130best patient selection criteria for proton therapy. The DBCG Proton
Trial has recruited patients since June 2020.
In conclusion, breast cancer patients (including patients
referred to breast only radiotherapy or with bilateral breast cancer)
with a mean heart dose of 4 Gy and/or ipsilateral lung V17Gy/V
20Gy  37% are candidates for the randomised DBCG Proton Trial.
We estimate that 22% of all patients requiring loco-regional IMN
radiotherapy will be eligible for the trial in departments treating
with 3DCRT in breath-hold.
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